Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies.

被引：0

作者：

Burmester, G. ^{[1
]}

Blanco, Ricardo ^{[2
]}

Rubbert-Roth, Andrea ^{[3
]}

Hendrikx, Thijs ^{[4
]}

Kwok, Kenneth ^{[5
]}

Bradley, John ^{[6
]}

Zwillich, Samuel H. ^{[6
]}

Benda, Birgitta ^{[7
]}

Mebus, Charles A. ^{[6
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Hosp Univ Marques De Valdecilla, Santander, Spain

[3] Univ Cologne, D-50931 Cologne, Germany

[4] Pfizer Bv, Capelle Aan Den Ijssel, Netherlands

[5] Pfizer Inc, New York, NY USA

[6] Pfizer Inc, Groton, CT 06340 USA

[7] Pfizer Inc, Collegeville, PA USA

来源：

ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

L12

引用

页码：4172 / 4172

页数：1

共 50 条

[1] Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population.
Cohen, S.
Krishnaswami, S.
Benda, B.
Riese, R.
Boy, M. G.
Gruben, D.
Wallenstein, G.
Mebus, C. A.
Zwillich, S. H.
Bradley, J. D.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1048 - S1049
[2] HERPES ZOSTER IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED ANALYSES OF TOFACITINIB PHASE 2, 3 AND LONG-TERM EXTENSION STUDIES IN A LATIN AMERICAN SUBPOPULATION
Zerbini, Cristiano A. F.
Radominski, Sergio C.
Cardiel, Mario
Castaneda, Oswaldo
Citera, Gustavo
Neira, Oscar
Ponce de Leon, Dario
Hoffman, Elaine
Rojo, Ricardo
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 124 - 124
[3] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
Hall, S.
Nash, P.
Rischmueller, M.
Bossingham, D.
Cook, N.
Witcombe, D.
Kwok, K.
Thirunavukkarasu, K.
INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
[4] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Terry, Ketti
Kwok, Kenneth
Strengholt, Sander
DeMasi, Ryan
Wang, Lisy
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[5] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 8 YEARS
Wollenhaupt, J.
Silverfield, J.
Lee, E. B.
Terry, K.
Kwok, K.
Abramsky, S.
Wang, M.
Nduaka, C.
DeMasi, R.
Wang, L.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 277 - 278
[6] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Terry, Ketti
Kwok, Kenneth
Abramsky, Staci
Wang, Min
Nduaka, Chudy
DeMasi, Ryan
Wang, Lisy
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[7] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 9 YEARS
Wollenhaupt, J.
Silverfield, J.
Lee, E. B.
Terry, K.
Kwok, K.
Strengholt, S.
DeMasi, R.
Wang, L.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 978 - 978
[8] Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
Cohen, S. B.
Fleischmann, R. M.
Kremer, J. M.
Koenig, A.
Kwok, K.
Wang, L.
Mebus, C. A.
Riese, R.
Robinson, T.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S192 - S193
[9] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Wollenhaupt, Juergen
Silverfield, Joel
Lee, Eun Bong
Wood, Susan P.
Terry, Ketti K.
Nakamura, Hiroyuki
Ohno, Yukako
Gruben, David
Benda, Birgitta
Wang, Lisy
Riese, Richard
ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
[10] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Wollenhaupt, Jurgen
Silverfield, Joel C.
Lee, Eun Bong
Wood, Susan P.
Soma, Koshika
Wang, Lisy
Nakamura, Hiroyuki
Komuro, Yoshihiro
Nduaka, Chudi I.
Gruben, David
Benda, Birgitta
Zwillich, Samuel H.
Riese, Richard
Bradley, John D.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549

← 1 2 3 4 5 →